The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Preclinical Screening of Compounds that Modulate the Pathological Interplay between Alpha-synuclein and Synapsin III for the Treatment of Parkinson’s Disease
Study Rationale: The protein alpha-synuclein forms abnormal aggregates in the brains of people with Parkinson's disease (PD). Although the mechanism by which this aggregation leads to the pathological...
-
Fall 2021 RFP: Outcome Measures, 2021Characterization of Sterols in CSF and Plasma as a Possible Biomarker for Parkinson’s Disease
Study Rationale: Sterols, including cholesterol, are very abundant in the brain, where they form important components of cell membranes and act as signaling molecules within and between cells...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Testing the Neuroprotective Effects of Modulating Atp6v0a1
Study Rationale: Parkinson’s disease (PD) is associated with the death of dopamine-producing neurons. Neuroprotective strategies that could maintain these critical cells would provide a much-needed...
-
Alpha-synuclein Seed Amplification Assay Program, 2021Development of a Simplified, Rapid Method for Measuring Alpha-synuclein in Clinical Samples
Study Rationale: Alpha-synuclein aggregates are considered to be an excellent biomarker for the diagnosis of Parkinson’s disease (PD). The challenge is to optimize the tests currently used to detect...
-
Fall 2021 RFP: Outcome Measures, 2021Development and Validation of a Sensitive Method for Measuring PINK
Study Rationale: Mutations in PINK1 are linked to familial Parkinson’s disease (PD), but their role in sporadic forms of the disorder are not clear. The PINK1 protein works with PRKN to dispose of...
-
Fall 2021 RFP: Expanding Biological Understanding of PD, 2021Studying How Defects in Autophagy Contribute to the Aggregation of Alpha-synuclein in Neurons with LRRK2 Mutations
Study Rationale: Mutations in the LRRK2 gene are the most frequent cause of inherited forms of Parkinson’s disease (PD). We have found that these mutations disrupt autophagy—a process that cells...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.